Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PDS Biotechnology Corp (PDSB)

PDS Biotechnology updates corporate presentation with PDS0301 and PDS0101 data

Neutral Impact 1 of 5 other Written later

PDS Biotechnology filed an 8-K on October 20, 2026 to report that it updated its corporate presentation deck, which is attached as Exhibit 99.1. The filing contains no new financial results, guidance, or transaction terms, and the deck's clinical figures are company-presented and preliminary.

Key points

  • Corporate presentation (October 2026) filed as Exhibit 99.1 on October 20, 2026.
  • Deck cites a 71.4% objective response rate at six months in an NCI-led Phase 2 trial of PDS0301 plus chemotherapy in colorectal cancer with liver metastases; the company notes the trial was not randomized.
  • Deck lists five PDS0301 data readouts expected between Q4 2026 and Q2 2028.
  • Deck states more than 380 patients have been dosed across PDS0301 and PDS0101 trials.

The filing

CompanyPDS Biotechnology Corp (PDSB)
Form8-K, current report
Filed with the SECOct 20, 2026, 7:59 PM ET
Accession number0001140361-26-040283

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.